{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:04:54Z","timestamp":1790643894953,"version":"4.1.0"},"reference-count":24,"publisher":"Japanese Society of Internal Medicine","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,10,1]]},"DOI":"10.2169\/internalmedicine.2931-23","type":"journal-article","created":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T22:15:58Z","timestamp":1709504158000},"page":"2667-2671","source":"Crossref","is-referenced-by-count":6,"title":["Nivolumab-induced Thrombotic Thrombocytopenic Purpura in Patients with Gastric Tube Cancer"],"prefix":"10.2169","volume":"63","author":[{"given":"Yuya","family":"Yoshida","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakura","family":"Toriyabe","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiju","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kasahara","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Ouchi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Saijo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Onodera","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tohoku University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikashi","family":"Ishioka","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23: 234-247, 2022.","DOI":"10.1016\/S1470-2045(21)00692-6"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390: 2461-2471, 2017.","DOI":"10.1016\/S0140-6736(17)31827-5"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Chen TW, Razak AR, Bedard PL, Siu LL, Hansen AR. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol 26: 1824-1829, 2015.","DOI":"10.1093\/annonc\/mdv182"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Barron CC, Stefanova I, Cha Y, et al. Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review. J Immunother Cancer 11: 2023.","DOI":"10.1136\/jitc-2022-006500"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Dirven I, Vander Mijnsbrugge AS, Mignon S, Tijtgat J, Kint N, Neyns B. Auto-immune hemolytic anemia and hemophagocytic lymphohistiocytosis as immune-related adverse event in patients with metastatic melanoma and concurrent chronic lymphocytic leukemia: a case series and literature review. Melanoma Res 33: 338-344, 2023.","DOI":"10.1097\/CMR.0000000000000895"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Zhang X, Gao BX, Guo CY, Su T. A 71-year-old male with a life-threatening recurrence of hemolytic anemia, thrombocytopenia, and acute kidney injury after pembrolizumab therapy: a case report. BMC Geriatr 23: 478, 2023.","DOI":"10.1186\/s12877-023-04181-w"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Nelson BE, Ejezie CL, Stephen BA, et al. Spectrum of immune checkpoint inhibitor anemias: results from a single center, early-phase clinical trials case series experience. J Hematol 11: 113-120, 2022.","DOI":"10.14740\/jh1006"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kubo T, Hino A, Fukushima K, et al. Nivolumab-induced systemic lymphadenopathy occurring during treatment of malignant melanoma: a case report. Int J Hematol 116: 302-306, 2022.","DOI":"10.1007\/s12185-022-03312-0"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Oyama S, Shirai T, Abe Y, et al. Immune checkpoint inhibitor-related haemophagocytic lymphohistiocytosis in a patient with non-small cell lung carcinoma. Respirol Case Rep 11: e01117, 2023.","DOI":"10.1002\/rcr2.1117"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. He L, Zhuang Y, Zhang D, Tang Z. PD-1 blockader-associated atypical hemophagocytic lymphohistiocytosis: a cautionary case report. Transfus Apher Sci 62: 103603, 2023.","DOI":"10.1016\/j.transci.2022.103603"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Shatzel JJ, Taylor JA. Syndromes of thrombotic microangiopathy. Med Clin North Am 101: 395-415, 2017.","DOI":"10.1016\/j.mcna.2016.09.010"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Sayani FA, Abrams CS. How I treat refractory thrombotic thrombocytopenic purpura. Blood 125: 3860-3867, 2015.","DOI":"10.1182\/blood-2014-11-551580"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. King J, de la Cruz J, Lutzky J. Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP). J Immunother Cancer 5: 19, 2017.","DOI":"10.1186\/s40425-017-0224-7"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Lafranchi A, Springe D, Rupp A, Ebn\u00f6ther L, Zschiedrich S. Thrombotic thrombocytopenic purpura associated to dual checkpoint inhibitor therapy for metastatic melanoma. CEN Case Rep 9: 289-290, 2020.","DOI":"10.1007\/s13730-020-00454-0"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Mullally WJ, Cooke FJ, Crosbie IM, et al. Case Report: thrombotic-thrombocytopenic purpura following ipilimumab and nivolumab combination immunotherapy for metastatic melanoma. Front Immunol 13: 871217, 2022.","DOI":"10.3389\/fimmu.2022.871217"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Lancelot M, Miller MJ, Roback J, Stowell SR. Refractory thrombotic thrombocytopenic purpura related to checkpoint inhibitor immunotherapy. Transfusion 61: 322-328, 2021.","DOI":"10.1111\/trf.16117"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ali Z, Zafar MU, Wolfe Z, Akbar F, Lash B. Thrombotic thrombocytopenic purpura induced by immune checkpoint inhibitiors: a case report and review of the literature. Cureus 12: e11246, 2020.","DOI":"10.7759\/cureus.11246"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Youssef A, Kasso N, Torloni AS, et al. Thrombotic thrombocytopenic purpura due to checkpoint inhibitors. Case Rep Hematol 2018: 2464619, 2018.","DOI":"10.1155\/2018\/2464619"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. De Filippis S, Moore C, Ezell K, Aggarwal K, Kelkar AH. Immune checkpoint inhibitor-associated thrombotic thrombocytopenic purpura in a patient with metastatic non-small-cell lung cancer. Cureus 13: e16035, 2021.","DOI":"10.7759\/cureus.16035"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Gergi M, Landry KK, Ades S, Barry M, Zakai NA, Herrera DA. Nivolumab-induced thrombotic thrombocytopenic purpura in a patient with anal squamous cell carcinoma: a lesson on hematologic toxicity from immunotherapy. Oncologist 25: 1009-1012, 2020.","DOI":"10.1002\/onco.13553"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Honjo O, Kubo T, Sugaya F, et al. Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report. J Immunother Cancer 7: 97, 2019.","DOI":"10.1186\/s40425-019-0582-4"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Leisring J, Brodsky SV, Parikh SV. The clinical evaluation and management of thrombotic microangiopathy. Arthritis Rheumatol 76: 153-165, 2023.","DOI":"10.1002\/art.42681"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Mazzierli T, Allegretta F, Maffini E, Allinovi M. Drug-induced thrombotic microangiopathy: an updated review of causative drugs, pathophysiology, and management. Front Pharmacol 13: 1088031, 2022.","DOI":"10.3389\/fphar.2022.1088031"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Moore DC, Elmes JB, Arnall JR, Strassels SA, Patel JN. Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: real-world study of the FDA adverse event reporting system. Int Immunopharmacol 110: 109015, 2022.","DOI":"10.1016\/j.intimp.2022.109015"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/19\/63_2931-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T03:33:19Z","timestamp":1728099199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/19\/63_2931-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":24,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2931-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]},"article-number":"2931-23"}}